Germline genetic testing analyzes DNA you inherited from your parents, looking for variants in genes that are present in every cell of your body and can be passed to your children. Unlike tests that examine only tumor tissue or check a handful of ancestry markers, germline testing looks at your inherited blueprint for changes linked to conditions like hereditary cancers, heart disease, or neurological disorders. Results fall into a classification system ranging from clearly harmful variants to ones with no known significance, and what those categories mean for your health and your family is more nuanced than a simple positive or negative.
What Makes Germline Testing Different
Every cell in your body carries roughly the same copy of DNA, the version you were born with. That is your germline. If a variant exists in your germline, it is in your blood, your skin, your saliva, and your organs. It was there before you were born, and if you have biological children, there is a chance you passed it along. This is fundamentally different from somatic mutations, which arise during a person’s lifetime in specific tissues. A tumor, for example, can acquire mutations that exist only within the cancer cells. Researchers have mapped interactions between germline and somatic variants that help explain both cancer risk and how tumors develop, showing that the inherited genome plays a role beyond simply “starting” the disease.1PubMed Central. Exploring the Link between the Germline and Somatic Genome in Cancer
The distinction matters practically. Somatic testing on a biopsy tells an oncologist what is driving a specific tumor right now. Germline testing tells you what risk you were born with, which cancers or conditions you might develop in the future, and whether your blood relatives share that risk. Both have clinical value, but they answer different questions.
Types of Germline Tests
Not every germline test looks at the same amount of DNA. The options range from narrow to broad:
- Single-gene tests: These target one specific gene, usually when a known condition runs in a family. If your mother had a confirmed BRCA1 mutation, your test might focus exclusively on that gene.
- Gene panels: These analyze a curated set of genes, often dozens, related to a group of conditions. A hereditary cancer panel might cover 40 or more genes linked to breast, ovarian, colorectal, and other cancers.
- Exome or genome sequencing: These cast the widest net, analyzing either all protein-coding regions of DNA (the exome) or the entire genome.
The choice depends on the clinical situation.2PubMed. Solving the molecular diagnostic testing conundrum for Mendelian disorders in the era of next-generation sequencing: single-gene, gene panel, or exome/genome sequencing A broader test picks up more, but it also generates more ambiguous findings, a tradeoff that becomes important when you get to the results.
How Results Are Classified
Germline test results do not come back as a simple “you have it” or “you don’t.” Laboratories classify each variant found using a five-tier system developed by the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG-AMP). That system weighs multiple lines of evidence, from how rare the variant is in the general population to whether laboratory experiments have shown it disrupts the gene’s function.3PubMed Central. Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework The categories are:
- Pathogenic: Strong evidence that this variant causes disease.
- Likely pathogenic: High probability of causing disease, though the evidence is slightly less definitive.
- Variant of uncertain significance (VUS): Not enough evidence to classify as either harmful or harmless.
- Likely benign: Probably not disease-causing.
- Benign: Strong evidence that the variant does not cause disease.
In clinical practice, pathogenic and likely pathogenic variants are treated similarly; both typically prompt changes in medical management. Benign and likely benign variants are treated as normal findings. The middle category, VUS, is where things get complicated.
What a Pathogenic Result Means in Practice
A pathogenic or likely pathogenic germline variant does not mean you will definitely develop a disease. It means you carry a significantly elevated risk compared to someone without that variant. How elevated depends on the specific gene and mutation. In pediatric cancer genetics, for instance, variants in the RB1 gene (linked to retinoblastoma) show penetrance around 90%, meaning the vast majority of carriers develop the cancer. By contrast, variants in the WT1 gene linked to Wilms tumors show penetrance closer to 50%, meaning roughly half of carriers develop the condition.4Nature Medicine. Pathogenic germline variations and cancer risks in pediatric patients referred for genetic testing That range, from near-certainty to a coin flip, illustrates why a pathogenic result is the beginning of a conversation with your medical team, not a diagnosis.
When a pathogenic variant is found, it tends to change medical management quickly. In a study of prostate cancer patients who underwent universal germline testing, those with positive results were far more likely to receive recommendations for treatment changes, altered follow-up schedules, and testing of family members compared to those with negative or uncertain results.5PubMed Central. Clinician-Reported Management Recommendations in Response to Universal Germline Genetic Testing in Patients With Prostate Cancer In concrete terms, about two-thirds of patients with positive results received changes to their follow-up plans, and roughly seven in ten were referred for family cascade testing.
Variants of Uncertain Significance
A VUS result is one of the most common and most misunderstood outcomes of germline testing. It means the laboratory found a variant in your DNA, but the existing evidence cannot determine whether it contributes to disease or is simply a harmless quirk of your individual genome. The expansion of testing technology has made VUS results more frequent, because broader panels and exome sequencing analyze more genes, inevitably catching more variants that have not been well-studied.6PubMed. Understanding and interpretation of a variant of uncertain significance (VUS) genetic test result by pediatric providers who do not specialize in genetics
The crucial point is that a VUS should not be treated as a positive result. It should not drive surgery decisions, aggressive screening protocols, or panic. Yet research shows that even healthcare providers who do not specialize in genetics sometimes struggle to interpret VUS results correctly, and patients frequently leave appointments confused about what the finding means for them. Genetic counselors report high confidence in their own ability to explain VUS results, but lower confidence that patients truly understand the explanation.7PubMed Central. Genetic counselors’ practices and confidence regarding variant of uncertain significance results and reclassification from BRCA testing
A VUS is not a permanent classification. As labs collect more data from more patients over time, many VUS results eventually get reclassified as either benign or pathogenic. This process happens regularly and is part of the normal lifecycle of genetic knowledge.8PubMed Central. Variant reclassification and recontact research: A scoping review However, how and when labs notify you about a reclassification varies widely, and there are no universal guidelines mandating that patients be recontacted when a previously uncertain variant is reclassified.
When a Negative Result Is Not All-Clear
A negative germline test means the lab did not find a pathogenic or likely pathogenic variant in the genes analyzed. That sounds reassuring, but it comes with a significant caveat: the test can only find what it looks for. If you had a 20-gene panel, you were not screened for variants in the thousands of other genes. And if your family has a strong pattern of disease but no known mutation has been identified, a negative result is often called “uninformative negative,” meaning the absence of a finding does not rule out hereditary risk.
This situation is common in breast cancer genetics. When BRCA1/2 testing is performed in a family where no mutation has been previously identified and the result comes back negative, family members may still carry elevated breast cancer risk due to variants in other predisposition genes or shared environmental factors.9PubMed Central. Breast Cancer Risk Perceptions among Relatives of Women with Uninformative Negative BRCA1/2 Test Results: The Moderating Effect of the Amount of Shared Information A truly informative negative result is one where a specific pathogenic variant has already been identified in a family member and you test negative for that exact variant. In that scenario, your risk drops back to the general population level for that particular gene.
Targeted Therapies and Screening Changes
One of the most tangible benefits of germline testing is its ability to open doors to specific treatments. The clearest example involves PARP inhibitors, a class of drugs that work by exploiting a weakness in cells that cannot repair DNA properly. In patients with germline BRCA1 or BRCA2 mutations, both healthy cells and cancer cells have a defect in one DNA repair pathway. PARP inhibitors block a second repair pathway, which healthy cells can tolerate but cancer cells cannot, leading the cancer cells to die. This approach has shown benefit in progression-free survival and quality of life for patients with BRCA-associated metastatic breast cancer.10Meditsinskiy sovet = Medical Council. PARP inhibitors in the treatment of metastatic breast cancer patients with germline BRCA1/2 mutations. Experience of treatment with talazoparib in clinical practice
Germline variants also influence screening strategies. Carriers of specific alterations linked to prostate cancer, for example, may qualify for earlier or more intensive screening programs. Those with advanced disease may become eligible for targeted therapies like PARP inhibitors or immune checkpoint inhibitors, depending on which germline alteration is present.11memo – Magazine of European Medical Oncology. Genetic testing and management of prostate cancer patients with pathogenic germline variants The same principle applies across many cancer types: a germline finding does not just quantify risk, it can directly shape the treatment plan.
Cascade Testing for Family Members
When a pathogenic germline variant is found, the implications extend beyond the person tested. Since germline variants are inherited, first-degree relatives (parents, siblings, and children) each have roughly a 50% chance of carrying the same variant if it follows a dominant inheritance pattern. Cascade testing is the process of systematically testing relatives to identify who else may carry the variant.
In practice, cascade testing rates are lower than you might expect. Among families where a pathogenic variant was identified, only about a quarter of patients had even one family member undergo cascade testing, according to a large study of over 22,000 individuals.12JAMA Network Open. Differences in Cascade Genetic Testing Among Families With Hereditary Cancer Risk When healthcare systems directly contact relatives rather than relying on the patient to relay the information, testing uptake improves substantially, with rates climbing from around 40% to over 60% for first-degree relatives.13PubMed Central. Cascade Testing for Hereditary Cancer Syndromes: Should We Move Toward Direct Relative Contact? A Systematic Review and Meta-Analysis
Among relatives who do get tested and find they carry the variant, only a small fraction continue the cascade by inviting additional family members to test. One initiative found that about 12% of newly positive relatives went on to invite others.14PubMed Central. Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative The cascade tends to peter out quickly, which means many at-risk family members never find out about a variant that could change their medical care.
Why Your Ancestry Affects Your Results
The databases used to classify genetic variants have a well-documented bias: they contain far more data from people of European descent than from other groups. This creates a real, measurable problem. When a lab encounters a variant in a patient of African, Asian, Hispanic, or Middle Eastern ancestry, it is more likely to lack the reference data needed to classify that variant confidently, and the result ends up as a VUS instead of a clear pathogenic or benign call.15JAMA Network Open. Rates and Classification of Variants of Uncertain Significance in Hereditary Disease Genetic Testing
This is not a theoretical concern. Studies of hereditary cancer panels consistently find higher VUS rates in non-European groups.16Genetics in Medicine. Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk And the disparity extends to cascade testing: rates are lower among Black and Middle Eastern families compared to white families, even when free testing is offered, suggesting that cost is not the only barrier.12JAMA Network Open. Differences in Cascade Genetic Testing Among Families With Hereditary Cancer Risk The underrepresentation of non-European groups in reference databases makes variant interpretation harder for these populations, a problem the genetics community is working to address but has not yet solved.17PubMed Central. Inequities in multi-gene hereditary cancer testing: Lower diagnostic yield and higher VUS rate in individuals who identify as Hispanic, African or Asian and Pacific Islander as compared to European
Incidental and Secondary Findings
When germline testing casts a wide net, particularly with exome or genome sequencing, the lab sometimes finds variants unrelated to the original reason for testing. These are called incidental or secondary findings. You might undergo sequencing to investigate a cardiac condition and learn, unexpectedly, that you carry a pathogenic variant in a cancer predisposition gene.18PubMed Central. Global Perspectives on Managing Incidental and Secondary Findings in Genomic Testing: A Comprehensive Review of Policies, Implementation Challenges, and Stakeholder Perspectives
The ACMG maintains a list of genes for which labs are encouraged to report secondary findings, because the associated conditions are medically actionable, meaning there is something you can actually do about the risk if you know about it. International policies generally recommend discussing secondary findings with patients, including their penetrance, medical implications, and management options.19PubMed Central. International policies guiding the selection, analysis, and clinical management of secondary findings from genomic sequencing: A systematic review But practices vary across countries and institutions. Some labs report secondary findings by default; others give patients the option to opt out before testing begins.
Clinical-Grade Testing Versus Direct-to-Consumer Kits
Direct-to-consumer (DTC) genetic tests, the kind you can order online and do with a saliva sample at home, are not the same as clinical germline testing. The differences are significant enough that medical guidelines consistently recommend against making healthcare decisions based on DTC results alone. Clinical-grade labs operate under strict federal certification and accreditation standards that ensure accuracy and reliability. DTC labs may not meet these standards, and even when they have some regulatory clearance, the scope and depth of what they analyze is typically much narrower than a clinical panel.
DTC tests often screen for only a few well-known variants in popular genes like BRCA1 and BRCA2, rather than sequencing the entire gene. This means you could carry a pathogenic variant that the consumer test simply does not look for, giving you false reassurance. If a DTC test does flag something concerning, the recommended next step is to confirm the finding through a clinical-grade test ordered by a healthcare provider, not to act on the DTC result directly.
Genetic Counseling and the Emotional Side
Germline testing is one of the few medical tests where the result can have profound implications not just for you but for your children, siblings, and parents. That emotional weight is real. Research on prenatal genetic counseling has found that anxiety tends to be highest before counseling and testing, and generally drops afterward, but perceived risk estimates often remain higher than actual risk even after a thorough counseling session.20PubMed. Psychological response to prenatal genetic counseling and amniocentesis In other words, feelings about risk and objective risk tend to diverge, and counseling helps but does not fully close that gap.
Pre-test counseling covers what the test can and cannot tell you, what the possible result categories mean, and how findings might affect your medical care and family. Post-test counseling walks through the actual results and next steps.21PubMed Central. Pre- and post-test genetic counseling for chromosomal and Mendelian disorders If you are considering germline testing, meeting with a genetic counselor beforehand is strongly recommended, not because the test itself is risky, but because walking into it with clear expectations makes the results far easier to interpret and act on.
Reproductive Planning
For people who know they carry a pathogenic germline variant, reproductive planning becomes an additional consideration. Preimplantation genetic testing for monogenic disorders (PGT-M) allows couples undergoing in vitro fertilization to screen embryos for a specific known variant before implantation. This is available for a wide range of conditions, including autosomal dominant disorders like Huntington disease, autosomal recessive conditions like cystic fibrosis, X-linked disorders like Duchenne muscular dystrophy, and certain high-risk cancer predisposition syndromes like hereditary breast and ovarian cancer.22PubMed Central. Preimplantation genetic testing: A narrative review
Prenatal testing through amniocentesis or chorionic villus sampling can also detect germline variants during pregnancy. These options do not eliminate the emotional difficulty of the decisions involved, but they give carriers choices that did not exist a generation ago.
Testing Children
Germline testing in children raises distinct ethical questions. The general consensus among genetics professionals has been cautious: testing minors for adult-onset conditions is discouraged unless the result would change medical management during childhood. The concern centers on what ethicists call a child’s “right to an open future,” the idea that learning about an adult-onset risk before a child can meaningfully participate in the decision removes autonomy they would otherwise have as adults.23PubMed Central. Ethical considerations of genetic and genomic testing in pediatric oncology: A narrative review
The calculus changes when the condition in question has childhood onset or when surveillance starting in childhood is medically recommended. A child in a family with a known RB1 variant linked to retinoblastoma, for instance, benefits from early testing because screening needs to begin in infancy. Families navigating these decisions usually work closely with genetic counselors and pediatric specialists to weigh the potential benefits of early knowledge against the psychological and ethical considerations of testing a child who cannot fully consent.
Privacy and Legal Protections
In the United States, the Genetic Information Nondiscrimination Act (GINA) prohibits health insurers and employers from using genetic information to deny coverage or make employment decisions. That law has been in effect since 2008, yet awareness of it remains low. A survey of the general U.S. population found widespread lack of knowledge about GINA, even among people who had already undergone genetic testing and among those who expressed concerns about genetic discrimination.24PubMed Central. Genetic testing and insurance implications: Surveying the US general population about discrimination concerns and knowledge of the Genetic Information Nondiscrimination Act (GINA)
GINA has notable gaps. It does not apply to life insurance, disability insurance, or long-term care insurance. It does not cover employers with fewer than 15 employees. And it does not apply to military personnel. Some states have enacted additional protections to fill these gaps, but coverage is uneven. If you are weighing whether to pursue germline testing and are concerned about potential discrimination, understanding both the federal protections and their limitations is worth discussing with a genetic counselor before testing.
Monogenic Versus Polygenic Risk
Standard germline testing focuses on monogenic conditions, diseases caused or strongly influenced by variants in a single gene. But many common diseases, including most cancers, heart disease, and type 2 diabetes, involve complex interactions among many genes plus environmental factors. Polygenic risk scores (PRS) attempt to capture this broader genetic architecture by summing the effects of hundreds or thousands of common variants, each contributing a tiny amount of risk.
Interestingly, research has found that people who carry a rare pathogenic variant in a single gene tend to cluster at the low end of polygenic risk scores. Meanwhile, people with high polygenic scores who develop disease are more likely to have a complex, multi-gene cause rather than a single identifiable mutation.25PubMed Central. Polygenic risk scores in routine genetic diagnostics: what lies ahead? The two approaches capture different slices of genetic risk, and combining them may eventually give a more complete picture. For now, though, polygenic risk scores are not yet standard in clinical practice the way monogenic germline testing is, and their interpretation requires careful context.